{
    "clinical_study": {
        "@rank": "87537", 
        "acronym": "FOREST", 
        "arm_group": [
            {
                "arm_group_label": "Fosfomycin sodium intravenous", 
                "arm_group_type": "Experimental", 
                "description": "4g every 6 hours iv (60 min infusion)"
            }, 
            {
                "arm_group_label": "Meropenem intravenous", 
                "arm_group_type": "Active Comparator", 
                "description": "1g every 8 hours (15-30 min infusion)"
            }
        ], 
        "brief_summary": {
            "textblock": "Enterobacterieaceae (and specially Escherichia coli) showing resistance due to\n      extended-spectrum \u03b2-lactamases (ESBLs) have spread worldwide during the last decades. This\n      is important because many of these isolates are also resistant to other first-line agents\n      such as fluoroquinolones or aminoglycosides, leaving few available options for therapy, and\n      this condition is associated with increased morbidity- mortality and length of hospital\n      stay. While carbapenems are considered the drugs of choice for ESBL and AmpC producers,\n      recent data suggests that certain alternatives may be suitable for some types of infections.\n\n      At the present time, finding therapeutic alternatives to carbapenems for the treatment of\n      invasive infections due to extended-spectrum beta-lactamase (ESBL) Escherichia coli\n      (ESBL-Ec) is critical. Fosfomycin was discovered more than 40 years ago but was not\n      investigated according to present standards, and thus is not used in clinical practice\n      except in desperate situations. It is one of the so-considered neglected antibiotics with\n      high potential interest for the future.\n\n      With the aim of demonstrate the clinical non-inferiority of intravenous fosfomycin compared\n      to meropenem in the treatment of bacteraemic urinary tract infections caused by ESBL-Ec. The\n      investigators propose a \"real practise\" randomised, controlled, multicentre phase III\n      clinical trial to compare the clinical and microbiological efficacy and safety of\n      intravenous fosfomycin (4 grammes every 6 hours) with meropenem (1 gramme every 8 hours) as\n      targeted therapy of the previously specified infection; change to oral therapy according to\n      predefined options is allowed in both arms after 5 days. Follow-up for the study is planned\n      up to 60 days."
        }, 
        "brief_title": "Fosfomycin Versus Meropenem in Bacteriemic Infections Caused by ESBL-E. Coli", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Infection Due to ESBL Escherichia Coli", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u226518 years old hospitalized patients\n\n          -  Negative pregnancy test in fertile women\n\n          -  Episode of clinically-significant monomicrobial urinary BSI due to ESBL- E.coli\n             susceptible to fosfomycin and meropenem\n\n          -  Urinary sepsis with ESBL- E. coli isolation from the blood cultures, requires at\n             least one clinical criteria and one of the following urinalysis criteria:\n\n        Clinical criteria\n\n          -  UTI symptoms (dysuriac, urgency, suprapubic pain or pollakiuria)\n\n          -  Lumbar back pain\n\n          -  Cost-vertebral angle tenderness\n\n          -  Altered mental status in people up to 70 years old\n\n          -  Intermittent or permanent indwelling foley catheter (or withdrawal during 24 hours\n             previous) even without urinary symptoms urinalysis criteria\n\n          -  Urine dipstick test positive for either nitrites or leukocyte esterase\n\n          -  Positive urine culture - Signed informed consent form (ICF) executed prior to\n             protocol screening assessments\n\n        Exclusion Criteria:\n\n          -  Polymicrobial bacteremia\n\n          -  No drainage of renal abscess or obstructive uropathy unresolved\n\n          -  Pregnant or careening women\n\n          -  Acute and chronic prostatitis\n\n          -  Haematogenous infection\n\n          -  Other concomitant infection\n\n          -  Renal transplantation recipients\n\n          -  Polycystic kidney\n\n          -  Hypersensitivity and/or intolerance to meropenem or fosfomycin\n\n          -  Palliative care or  life expectance < 90 days\n\n          -  Septic shock at time of randomization\n\n          -  New York Heart Association (NYHA) functional Class III or IV, hepatic cirrhosis or\n             renal impairment receiving dialysis\n\n          -  Active empiric treatment >72 hours\n\n          -  Late randomization >24 hours after ESBL-E.coli blood culture\u00b4s identification\n\n          -  Participation in other clinical trial with active treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "198", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02142751", 
            "org_study_id": "FOREST"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fosfomycin sodium intravenous", 
                "description": "4g every 6 hours iv (60 min infusion)", 
                "intervention_name": "Fosfomycin sodium intravenous", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Generic name: Fosfomycin", 
                    "Pharmaceutical form: solution for infusion", 
                    "ATC code: J01J3"
                ]
            }, 
            {
                "arm_group_label": "Meropenem intravenous", 
                "description": "1g every 8 hours (15-30 min infusion)", 
                "intervention_name": "Meropenem intravenous", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Generic name: Meropenem", 
                    "Pharmaceutical form: solution for infusion", 
                    "ATC code: J01D5"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fosfomycin", 
                "Meropenem"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Escherichia coli", 
            "Extended-spectrum \u03b2-lactamases (ESBLs)", 
            "Bacteremia", 
            "Urinary tract infection", 
            "Bloodstream infection", 
            "Fosfomycin", 
            "Meropenem", 
            "Pharmacokinetics", 
            "intestinal colonization", 
            "Recurrence"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "link": {
            "description": "Spanish Network Research in Infectious Diseases (Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa [REIPI])", 
            "url": "http://www.reipi.org/"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Terrassa", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08221"
                    }, 
                    "name": "Hospital Mutua de Terrassa"
                }, 
                "investigator": {
                    "last_name": "Anna San Gil Betriu, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Palmas de Gran Canarias", 
                        "country": "Spain", 
                        "state": "Gran Canarias", 
                        "zip": "35010"
                    }, 
                    "name": "Hospital Universitario de Gran Canaria Dr. Negr\u00edn"
                }, 
                "investigator": {
                    "last_name": "Miguel Angel C\u00e1rdenas Santana, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vilanova", 
                        "country": "Spain", 
                        "state": "Lleida"
                    }, 
                    "name": "Hospital Arnau de Vilanova"
                }, 
                "investigator": {
                    "last_name": "Fernando Barcenilla Gaite, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "El Palmar", 
                        "country": "Spain", 
                        "state": "Murcia", 
                        "zip": "30120"
                    }, 
                    "name": "Hospital Cl\u00ednico Universitario Virgen de la Arrixaca"
                }, 
                "investigator": {
                    "last_name": "Alicia Hern\u00e1ndez Torres, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Laguna", 
                        "country": "Spain", 
                        "state": "Tenerife", 
                        "zip": "38320"
                    }, 
                    "name": "Hospital Universitario de Canarias"
                }, 
                "investigator": {
                    "last_name": "Mar\u00eda Lecuona Fern\u00e1ndez, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alicante", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital General Universitario de Alicante"
                }, 
                "investigator": {
                    "last_name": "Vicente Voix Mart\u00ednez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alicante", 
                        "country": "Spain", 
                        "zip": "03010"
                    }, 
                    "name": "Hospital Marina Baixa"
                }, 
                "investigator": {
                    "last_name": "Concepci\u00f3n Amador Prous, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08025"
                    }, 
                    "name": "Hospital de la Santa Creu i San Pau"
                }, 
                "investigator": {
                    "last_name": "Virginia Pomar Solchaga, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Hospital Vall d'Hebron"
                }, 
                "investigator": {
                    "last_name": "Carlos Pigrau Serrallach, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario de Bellvitge"
                }, 
                "investigator": {
                    "last_name": "Evelyn Shaw Perujo, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08003"
                    }, 
                    "name": "Hospital Parc Salud Mar"
                }, 
                "investigator": {
                    "last_name": "Mar\u00eda Luisa Sorli Red\u00f3, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bilbao", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital de Cruces"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burgos", 
                        "country": "Spain", 
                        "zip": "09006"
                    }, 
                    "name": "Hospital Universitario de Burgos"
                }, 
                "investigator": {
                    "last_name": "Carlos Due\u00f1as Guti\u00e9rrez, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "clrntr@gmail.com", 
                    "last_name": "Clara Natera, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "C\u00f3rdoba", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Reina Sof\u00eda"
                }, 
                "investigator": {
                    "last_name": "Clara Natera, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Hospital Ram\u00f3n y Cajal"
                }, 
                "investigator": {
                    "last_name": "Vicente Pintado Garc\u00eda, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital Universitario 12 de Octubre"
                }, 
                "investigator": {
                    "last_name": "Jos\u00e9 Tiago Sequeira L\u00f3pez da Silva, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oviedo", 
                        "country": "Spain", 
                        "zip": "33006"
                    }, 
                    "name": "Hospital Universitario Central de Asturias"
                }, 
                "investigator": {
                    "last_name": "Ana Mar\u00eda Fleites Guti\u00e9rrez, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca", 
                        "country": "Spain", 
                        "zip": "07010"
                    }, 
                    "name": "Hospital Son Espases"
                }, 
                "investigator": {
                    "last_name": "Nuria Borrel Sol\u00e9, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santander", 
                        "country": "Spain", 
                        "zip": "39008"
                    }, 
                    "name": "Hospital Marqu\u00e9s de Valdecillas"
                }, 
                "investigator": {
                    "last_name": "Luis Mart\u00ednez Mart\u00ednez, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jesodo@hotmail.com", 
                    "last_name": "Jes\u00fas Sojo Dorado, MD", 
                    "phone": "+34 955009024"
                }, 
                "contact_backup": {
                    "last_name": "Adoraci\u00f3n Valiente"
                }, 
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41009"
                    }, 
                    "name": "Hospital Universitario Virgen Macarena"
                }, 
                "investigator": [
                    {
                        "last_name": "Jes\u00fas Sojo Dorado, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Zaira R Palacios Baena, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Vicente Merino Bohorquez", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Adoraci\u00f3n Valiente, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46026"
                    }, 
                    "name": "Hospital Universitario y Polit\u00e9cnico La Fe"
                }, 
                "investigator": {
                    "last_name": "Miguel Salavert Llet\u00ed, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain", 
                        "zip": "50009"
                    }, 
                    "name": "Hospital Royo Villanova"
                }, 
                "investigator": {
                    "last_name": "Rosa Mar\u00eda Mart\u00ednez Alvarez, MDPhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 3, Randomized, Controlled Multicentric, Open-label Clinical Trial to Prove Non-Inferiority of Fosfomycin vs Meropenem in the Treatment of Bacteriemic Urinary Infection Due to Extended-Spectrum \u03b2eta-lactamase (ESBL) Escherichia Coli", 
        "overall_contact": {
            "email": "claram.rosso.sspa@juntadeandalucia.es", 
            "last_name": "Clara M. Rosso Fern\u00e1ndez, MD, PhD", 
            "phone": "+34955013414"
        }, 
        "overall_contact_backup": {
            "email": "angel.barriga.exts@juntadeandalucia.es", 
            "last_name": "Angel Barriga, BD", 
            "phone": "+34955013414"
        }, 
        "overall_official": {
            "affiliation": "Spanish Network for Research in Infectious Diseases", 
            "last_name": "JESUS RODRIGUEZ-BA\u00d1O, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical Cure: Complete resolution of infection symptoms (bacteremia and/or urinary tract infection-UTI-), present at the day on which blood culture was drawn.\nMicrobiological cure: Negative blood culture at day 5-7 after end of treatment. Besides this, if UTI was confirmed with a positive urine culture with the same microorganism than the blood culture, this culture should become negative.", 
            "measure": "Clinical and microbiological cure rate", 
            "safety_issue": "No", 
            "time_frame": "Day 5-7 after end of treatment (test of cure)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142751"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The infection was completely resolved after 5 days of complete treatment", 
                "measure": "Early clinical response", 
                "safety_issue": "No", 
                "time_frame": "After 5 days of complete treatment (from the first day of study drugs administration)"
            }, 
            {
                "description": "Death for any reason.", 
                "measure": "Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "At day 30 of follow-up"
            }, 
            {
                "description": "It is defined as the time from admission to hospital discharge", 
                "measure": "Length of hospital stay", 
                "safety_issue": "Yes", 
                "time_frame": "At day 30 of follow-up"
            }, 
            {
                "description": "Gathering any related adverse event from the informed consent form signature to the end of follow-up.", 
                "measure": "Safety of intravenous fosfomycin in this indication", 
                "safety_issue": "Yes", 
                "time_frame": "To the last visit, at 60 plus-minus 10 days (from the first day of study drugs administration)"
            }, 
            {
                "description": "Relapse: new symptoms of UTI in patient with previously considered as clinical or microbiological cured  in the visit of day 5-7 plus positive urine or blood cultures with the same microorganism isolated than the initial culture.\nRe-infection: same definition but with different strain in the culture results.", 
                "measure": "Recurrences (relapse and reinfection) rate", 
                "safety_issue": "No", 
                "time_frame": "To the last visit, at 60 plus-minus 10 days (from the first day of study drugs administration)"
            }, 
            {
                "description": "Therapeutic drug monitoring of fosfomycin, basic pharmacokinetic parameters will be determined.", 
                "measure": "Fosfomycin steady-state plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "At 3 days after treatment started"
            }, 
            {
                "description": "Study treatment impact in the gut colonization of MDRGNB (Multi drug resistant Gram negative bacilli)", 
                "measure": "Microbiota impact of study treatment bacilli", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, day 5-7, day 12"
            }, 
            {
                "description": "Frequency of strains that develop resistance and detection of resistance mechanisms in fosfomycin treatment arm.", 
                "measure": "Emergence of resistant clinical isolates of Escherichia coli to fosfomycin and meropenem", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of fosfomicin, an expected average of 14 days"
            }, 
            {
                "description": "Cultures are negative", 
                "measure": "Early microbiological response", 
                "safety_issue": "No", 
                "time_frame": "within the first 5 days after treatment started"
            }, 
            {
                "description": "Gathering any related adverse event from the informed consent form signature to the end of follow-up.", 
                "measure": "Safety of intravenous antibiotic administration in this indication", 
                "safety_issue": "Yes", 
                "time_frame": "To the last visit, at 60 plus-minus 10 days (from the first day of study drugs administration)"
            }
        ], 
        "source": "Fundaci\u00f3n P\u00fablica Andaluza para la gesti\u00f3n de la Investigaci\u00f3n en Sevilla", 
        "sponsors": {
            "collaborator": {
                "agency": "Spanish Network for Research in Infectious Diseases", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Fundaci\u00f3n P\u00fablica Andaluza para la gesti\u00f3n de la Investigaci\u00f3n en Sevilla", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}